Design of Tissue-specific Regulatory Cassettes for High-level rAAV-mediated Expression in Skeletal and Cardiac Muscle
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Systemic delivery of recombinant adeno-associated virus (rAAV) 6 vectors mediates efficient transduction of the entire striated musculature, making this an attractive strategy for muscle gene therapy. However, owing to widespread transduction of non-muscle tissues, optimization of this method would benefit from the use of muscle-specific promoters. Most such promoters either lack high-level expression in certain muscle types or are too large for inclusion in rAAV vectors encoding microdystrophin. Here, we describe novel regulatory cassettes based on enhancer/promoter regions of murine muscle creatine kinase (CK) and alpha-myosin heavy-chain genes. The strongest cassette, MHCK7 (770 bp), directs high-level expression comparable to cytomegalovirus and Rous sarcoma virus promoters in fast and slow skeletal and cardiac muscle, and low expression in the liver, lung, and spleen following systemic rAAV6 delivery in mice. Compared with CK6, our previous best cassette, MHCK7 activity is approximately 400-, approximately 50-, and approximately 10-fold higher in cardiac, diaphragm, and soleus muscles, respectively. MHCK7 also directs strong microdystrophin expression in mdx muscles. While further study of immune responses to MHCK7-regulated microdystrophin expression is needed, this cassette is not active in dendritic cell lines. MHCK7 is thus a highly improved regulatory cassette for experimental studies of rAAV-mediated transduction of striated muscle.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [135]
Citations
Cites
Three myosin heavy chain isoforms in type 2 skeletal muscle fibres
Schiaffino, S., Gorza, L., Sartore, S., Saggin, L., Ausoni, S., Vianello, M., Gundersen, K., & LØmo, T. (1989) · Journal of Muscle Research and Cell Motility · doi:10.1007/bf01739810 · Cited by 954
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Self-citationKessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., & Xiao, X. (2005) · Nature Biotechnology · doi:10.1038/nbt1073 · Cited by 608
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Bottinelli, R., Schiaffino, S., & Reggiani, C. (1991) · The Journal of Physiology · doi:10.1113/jphysiol.1991.sp018617 · Cited by 486
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006) · Circulation Research · doi:10.1161/01.res.0000237661.18885.f6 · Cited by 406
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Self-citationTabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.028 · Cited by 506
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Hong, E.-G., Ko, H. J., Cho, Y.-R., Kim, H.-J., Ma, Z., Yu, T. Y., Friedline, R. H., Kurt-Jones, E., Finberg, R., Fischer, M. A., et al. (2009) · Diabetes · doi:10.2337/db08-1261 · Cited by 411
Self-citationMendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Bengtsson, N. E., Hall, J. K., Odom, G. L., Phelps, M. P., Andrus, C. R., Hawkins, R. D., Hauschka, S. D., Chamberlain, J. R., & Chamberlain, J. S. (2017) · Nature Communications · doi:10.1038/ncomms14454 · Cited by 387
Self-citationBioengineered human myobundles mimic clinical responses of skeletal muscle to drugs
Madden, L., Juhas, M., Kraus, W. E., Truskey, G. A., & Bursac, N. (2015) · eLife · doi:10.7554/elife.04885 · Cited by 356
“, 2013) driven by a myosin heavy chaincreatine kinase promoter MHCK7 (Salva et al., 2007) for muscle specific expression.”
BackgroundMethodInfluentialWallace, L. M., Garwick, S. E., Mei, W., Belayew, A., Coppee, F., Ladner, K. J., Guttridge, D., Yang, J., & Harper, S. Q. (2011) · Annals of Neurology · doi:10.1002/ana.22275 · Cited by 240
“The MHCK7 promoter turned on 3 days postinjection, and consistent with previous reports in mice, was active in zebrafish skeletal muscle and heart.(39) By 4 days, 47% of MHCK7.”
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Self-citationEngineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer
Pulicherla, N., Shen, S., Yadav, S., Debbink, K., Govindasamy, L., Agbandje-McKenna, M., & Asokan, A. (2011) · Molecular Therapy · doi:10.1038/mt.2011.22 · Cited by 224
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
Mendell, J. R., Muntoni, F., McDonald, C. M., Mercuri, E. M., Ciafaloni, E., Komaki, H., Leon-Astudillo, C., Nascimento, A., Proud, C., Schara-Schmidt, U., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03304-z · Cited by 183
“…with specific pathogenic variants, but there is an unmet need for therapies that can more effectively stabilize or slow disease progression and that could be applicable to most of the DMD patient population, which sparked the research of new innovative therapies, including gene therapy 4–10 .”
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
Bez Batti Angulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1183101 · Cited by 173
“gov: NCT03375164) (Figure 1) (Table 2) (Harper et al., 2002; Salva et al., 2007).”
Chicoine, L., Montgomery, C., Bremer, W., Shontz, K., Griffin, D., Heller, K., Lewis, S., Malik, V, Grose, W., Shilling, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.244 · Cited by 167
Construction and analysis of compact muscle-specific promoters for AAV vectors
Wang, B., Li, J., Fu, F. H., Chen, C., Zhu, X., Zhou, L., Jiang, X. L., & Xiao, X. (2008) · Gene Therapy · doi:10.1038/gt.2008.104 · Cited by 165
Incorporation of macrophages into engineered skeletal muscle enables enhanced muscle regeneration
Juhas, M. E., Abutaleb, N. O., Wang, J. T., Ye, J., Shaikh, Z., Sriworarat, C., Qian, Y., & Bursac, N. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0290-2 · Cited by 160
Percival, J. M., Anderson, K. N. E., Huang, P., Adams, M. E., & Froehner, S. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40736 · Cited by 147
“To characterize the fiber composition of skeletal muscles, 10-μ m-thick frozen sections were immunolabeled with mouse monoclonal antibodies (a gift from Stephen Hauschka, University of Washington) raised against type I (BA-D5), type IIa (SC-71), and type IIb (BF-F3) MyHC proteins (36).”
Genetic Enhancement of Stem Cell Engraftment, Survival, and Efficacy
Penn, M. S., & Mangi, A. A. (2008) · Circulation Research · doi:10.1161/circresaha.108.175174 · Cited by 146
Adeno-Associated Virus Vectors as Therapeutic and Investigational Tools in the Cardiovascular System
Zacchigna, S., Zentilin, L., & Giacca, M. (2014) · Circulation Research · doi:10.1161/circresaha.114.302331 · Cited by 141
“ac muscles and seem useful for gene transfer in diseases such as Duchenne muscular dystrophy, which affects both tissues.(80)”
BackgroundTherapeutic approaches for Duchenne muscular dystrophy
Roberts, T. C., Wood, M. J. A., & Davies, K. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00775-6 · Cited by 147
“…a codon-optimized human micro-dystrophin minigene driven by a synthetic MHCK7 promoter, consisting of the muscle creatine kinase (MCK) promoter fused with the MCK and α-myosin heavy chain complex (αMHC) enhancers to promote high expression levels specifically in skeletal and cardiac muscle 104 .”
MethodCardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy
Meyers, T. A., & Townsend, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174098 · Cited by 149
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 166
AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome
Wang, S., Li, Y., Xu, Y., Ma, Q., Lin, Z., Schlame, M., Bezzerides, V. J., Strathdee, D., & Pu, W. T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315956 · Cited by 126
Bingen, B. O., Engels, M. C., Schalij, M. J., Jangsangthong, W., Neshati, Z., Feola, I., Ypey, D. L., Askar, S. F. A., Panfilov, A. V., Pijnappels, D. A., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu179 · Cited by 134
“MHCK7: chimeric striated muscle-specific promoter.(13) CatCh: coding sequence of an ultra-light-sensitive and highly Ca2+-permeable mutant of the Chlamydomonas reinhardtiichlamyopsin 4 light-gated ionchannel, also knownasChR2.”
BackgroundMethodInfluentialDevelopment of Novel Micro-dystrophins with Enhanced Functionality
Ramos, J. N., Hollinger, K., Bengtsson, N. E., Allen, J. M., Hauschka, S. D., & Chamberlain, J. S. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.002 · Cited by 119
“The contrasting results of mDys6 and mDys7 between muscle groups reinforces previous observations that the performance of a particular mDys construct can vary between different types of skeletal muscles.(19,43) This point was also exemplified with mDys2 treatment, where the susceptibility to contraction-induced injury…”
ResultSelf-citationHypoxia induces re-entry of committed cells into pluripotency
Mathieu, J., Zhang, Z., Nelson, A. M., Lamba, D. A., Reh, T. A., Ware, C. B., & Ruohola‐Baker, H. (2013) · Stem Cells · doi:10.1002/stem.1446 · Cited by 125
Efficient precise in vivo base editing in adult dystrophic mice
Xu, L., Zhang, C., Li, H., Wang, P., Gao, Y., Mokadam, N. A., Ma, J., Arnold, W. D., & Han, R. (2021) · Nature Communications · doi:10.1038/s41467-021-23996-y · Cited by 112
Therapeutic approaches to muscular dystrophy
Goyenvalle, A., Seto, J. T., Davies, K. E., & Chamberlain, J. S. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr105 · Cited by 130
Self-citationBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Zaidman, C. M., Proud, C. M., McDonald, C. M., Lehman, K. J., Goedeker, N. L., Mason, S., Murphy, A. P., Guridi, M., Wang, S., Reid, C., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26755 · Cited by 102
He, B., Tang, R., Weisleder, N. L., Xiao, B., Yuan, Z., Cai, C., Zhu, H., Lin, P., Qiao, C., Li, J., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.5 · Cited by 105
Mitochondrial Maturation in Human Pluripotent Stem Cell Derived Cardiomyocytes
Dai, D.-F., Danoviz, M. E., Wiczer, B., Laflamme, M. A., & Tian, R. (2017) · Stem Cells International · doi:10.1155/2017/5153625 · Cited by 98
The potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 98
“These MCK promoters exhibit strong activity in skeletal muscle but not in cardiac muscle [80].”
Xu, L., Zhao, L., Gao, Y., Xu, J., & Han, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1048 · Cited by 91
“Salva et al. demonstrated that the MHCK7 promoter had ∼400-, ∼50- and ∼10-fold higher activity in cardiac, diaphragm, and soleus muscles, respectively when compared to their previous ‘best’ construct creatine kinase 6 (CK6) (57).”
BackgroundResultInfluentialMicroRNA-regulated viral vectors for gene therapy
Geisler, A., & Fechner, H. (2016) · World Journal of Experimental Medicine · doi:10.5493/wjem.v6.i2.37 · Cited by 93
Martin, P. T., Xu, R., Rodino-Klapac, L. R., Oglesbay, E., Camboni, M., Montgomery, C. L., Shontz, K., Chicoine, L. G., Clark, K. R., Sahenk, Z., et al. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00456.2008 · Cited by 92
“Additional Galgt2 and microdystrophin vector constructs were made where the CMV promoter/enhancer was replaced by the muscle creatine kinase (MCK) promoter (44).”
Clinical development on the frontier: gene therapy for duchenne muscular dystrophy
Asher, D. R., Thapa, K., Dharia, S. D., Khan, N., Potter, R. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1725469 · Cited by 100
Kuramoto, K., Liang, H., Hong, J., & He, C. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.011 · Cited by 90
Potter, R. A., Griffin, D. A., Heller, K. N., Peterson, E. L., Clark, E. K., Mendell, J. R., & Rodino‐Klapac, L. R. (2021) · Human Gene Therapy · doi:10.1089/hum.2019.255 · Cited by 89
“In this study, we used MHCK7, which includes an a-MHC enhancer that has been shown to lead to high levels of expression in cardiomyocytes and increased dystrophin expression in skeletal muscle compared to muscle-specific promoters, MCK or CK7.(32) Indeed, we provide further support that MHCK7 limits off-target transge…”
BackgroundMethodInfluentialGene doping: the hype and the reality
Wells, D. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.144 · Cited by 96
“Much effort has been put into development of tissue-specific promoters and a highly efficient recombinant muscle-specific promoter based on the muscle creatine kinase gene has recently been described (Salva et al., 2007).”
BackgroundGrose, W. E., Clark, K. R., Griffin, D., Malik, V., Shontz, K. M., Montgomery, C. L., Lewis, S., Brown, R. H., Janssen, P. M. L., Mendell, J. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039233 · Cited by 76
“We constructed a human dysferlin cassette driven by the muscle specific MHCK7 promoter [33] (Fig.”
MethodGenetic treatments in muscular dystrophies
Muntoni, F., & Wells, D. J. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282efc157 · Cited by 76
Emerging strategies for cell and gene therapy of the muscular dystrophies
Muir, L. A., & Chamberlain, J. S. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001100 · Cited by 76
Self-citationPozsgai, E. R., Griffin, D. A., Heller, K. N., Mendell, J. R., & Rodino-Klapac, L. R. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.013 · Cited by 76
Wang, D., Li, S., Gessler, D. J., Xie, J., Zhong, L., Li, J., Tran, K., Van Vliet, K., Ren, L., Su, Q., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.004 · Cited by 73
Mattar, C. N. Z., Waddington, S. N., Biswas, A., Johana, N. B., Ng, X., Fisk, A. S., Fisk, N. M., Tan, L. G., Rahim, A. A., Buckley, S. M. K., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.216 · Cited by 77
Sun, B., Young, S. P., Li, P., Di, C., Brown, T., Salva, M. Z., Li, S., Bird, A., Yan, Z., Auten, R., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.133 · Cited by 73
Self-citationAdvancements in AAV-mediated Gene Therapy for Pompe Disease
Salabarria, S., Nair, J., Clément, N., Smith, B. K., Raben, N., Fuller, D., Byrne, B., & Corti, M. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190426 · Cited by 54
AAV Vectors for Cardiac Gene Transfer: Experimental Tools and Clinical Opportunities
Pacak, C. A., & Byrne, B. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.124 · Cited by 70
Manini, A., Abati, E., Nuredini, A., Corti, S. P., & Comi, G. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.814174 · Cited by 83
Birch, S. M., Lawlor, M. W., Conlon, T. J., Guo, L., Crudele, J. M., Hawkins, E. C., Nghiem, P. P., Ahn, M., Meng, H., Beatka, M. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo1815 · Cited by 70
“In the current study, muscle-specific expression was achieved using the CK8e regulatory cassette derived from enhancer and promoter regions of the muscle creatine kinase gene (16).”
BackgroundMethodSelf-citationKwon, J. B., Ettyreddy, A. R., Vankara, A., Bohning, J. D., Devlin, G. W., Hauschka, S. D., Asokan, A., & Gersbach, C. A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.016 · Cited by 62
“MHCK7 also contains a highly conserved, ~190-bp portion of the mouse alpha myosin heavy chain enhancer that contains an MCAT and two GATA control elements that are not present in CK8e.25 A potential caveat to the dual reporter mouse is the possibility that differentiating myoblasts may express residual nGFP, while upr…”
BackgroundSelf-citationHimeda, C. L., Ranish, J. A., Pearson, R. C. M., Crossley, M., & Hauschka, S. D. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00302-10 · Cited by 68
Self-citationDesigning Heart Performance by Gene Transfer
Davis, J., Westfall, M. V., Townsend, D., Blankinship, M., Herron, T. J., Guerrero-Serna, G., Wang, W., Devaney, E., & Metzger, J. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00039.2007 · Cited by 59
“This technique is capable of transducing other tissues, such as skeletal muscle, although the development of cardiac specific expression cassettes may be able to overcome this possible problem (783).”
BackgroundSelf-citationGene therapy for muscular dystrophy: current progress and future prospects
Trollet, C., Athanasopoulos, T., Popplewell, L. J., Malerba, A., & Dickson, G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903029164 · Cited by 62
“MHCK7 (770 bp) a muscle-specific promoter, directs high-level expression similar to that from constitutive promoters in fast and slow skeletal and cardiac muscle, and demonstrated low expression in the liver, lung and spleen following systemic rAAV6 delivery in mice [32].”
Muscle-Specific Promoters for Gene Therapy
Skopenkova, V. V., Egorova, T. V., & Bardina, M. V. (2021) · Acta Naturae · doi:10.32607/actanaturae.11063 · Cited by 62
Katwal, A. B., Konkalmatt, P. R., Piras, B. A., Hazarika, S., Li, S. S., John Lye, R., Sanders, J. M., Ferrante, E. A., Yan, Z., Annex, B. H., et al. (2013) · Gene Therapy · doi:10.1038/gt.2013.16 · Cited by 56
Gene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 69
“T-cell reactivity against the AAV vector has been successfully blocked or limited by transient immune suppression, by the use of muscle-restricted promoters and by high-dose treatment with corticosteroids [68,69,103,104].”
BackgroundSelf-citationGene therapy to treat cardiac arrhythmias
Bongianino, R., & Priori, S. G. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.61 · Cited by 58
Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice
Tasfaout, H., Lionello, V. M., Kretz, C., Koebel, P., Messaddeq, N., Bitz, D., Laporte, J., & Cowling, B. S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.008 · Cited by 67
Targeting transgene to the heart and liver with AAV 9 by different promoters
Chen, B., He, C., Chen, X., Pan, S., Liu, F., Ma, X., Li, X., Gai, M., Tao, J., Ma, Y., et al. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12453 · Cited by 52
“However, such unintended liver transgene expression can be diminished through reducing the dose of recombinant AAV9 vector,(7) using cardiac-specific promoters(10,23) or microRNA-122 target sequences.(24) Interestingly, although the liver had higher DNA copy numbers, the heart had the highest GFP expression levels amo…”
BackgroundTargeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD
Himeda, C. L., Jones, T. I., & Jones, P. L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.001 · Cited by 55
“Enhancer modifications are as follows: (1) Left E-box mutated to Right E-box,(80) (2) enhancer CArG andAP2 sites removed, (3) 63 bp between Right E-box andMEF2 site removed,(39) (4) sequence between TF bindingmotifs minimized, (5) +1 to +50 promoter sequence used,(39) and (6) consensus Inr site added.(39) The sequence…”
BackgroundSelf-citationIntravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System
Gessler, D. J., Tai, P. W. L., Li, J., & Gao, G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_8 · Cited by 57
Self-citationPhysiological and tissue-specific vectors for treatment of inherited diseases
Toscano, M. G., Romero, Z. G., Muñoz, P., Cobo, M., Benabdellah, K., & Martín, F. (2010) · Gene Therapy · doi:10.1038/gt.2010.138 · Cited by 51
Hsu, C. Y. M., & Uludağ, H. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.655247 · Cited by 53
“…(hAAT), creatine kinase, insulin, (Follenzi et al., 2002; Le et al., 1997; Gregorevic et al., 2004; Londrigan et al., 2007) as well as synthetic promoters have been constructed to enhance specificity and transgene expression in liver, muscle, and epithelium (Mount et al., 2002; Salva et al., 2007).”
BackgroundApproaching a New Age in Duchenne Muscular Dystrophy Treatment
Wagner, K. R. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.08.013 · Cited by 52
Takasugi, M., Nonaka, Y., Takemura, K., Yoshida, Y., Stein, F., Schwarz, J. J., Adachi, J., Satoh, J., Ito, S., Tombline, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52845-x · Cited by 43
Targeted Gene Therapy for the Treatment of Heart Failure
Rapti, K., Chaanine, A. H., & Hajjar, R. J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.02.005 · Cited by 48
Heller, K. N., Montgomery, C. L., Janssen, P. M. L., Clark, K. R., Mendell, J. R., & Rodino‐Klapac, L. R. (2013) · Molecular Therapy · doi:10.1038/mt.2012.281 · Cited by 48
Potter, R. A., Peterson, E. L., Griffin, D., Cooper-Olson, G., Lewis, S., Cochran, K., Mendell, J. R., & Rodino‐Klapac, L. R. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101195 · Cited by 40
Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy
Hart, C. C., Lee, Y. I., Xie, J., Gao, G., Lin, B. L., Hammers, D. W., & Sweeney, H. L. (2024) · JCI Insight · doi:10.1172/jci.insight.165869 · Cited by 49
“The MHCK7 promotor driving MDC1 in clinical trials has been shown to have much greater expression in hearts than in skeletal muscle in mice (46, 53).”
BackgroundDesign and Testing of Regulatory Cassettes for Optimal Activity in Skeletal and Cardiac Muscles
Himeda, C. L., Chen, X., & Hauschka, S. D. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61737-982-6_1 · Cited by 40
Self-citationAAV-directed muscular dystrophy gene therapy
Tang, Y. M., Cummins, J. H., Huard, J., & Wang, B. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003604690 · Cited by 50
“In addition, a recent paper by Dr Hauschka’s group has described a novel set of regulatory cassettes which are based on enhancer/promoter regions of the murine MCK promoter and a-myosin heavy-chain genes, such as MHCK7, which appears to be an improved regulatory cassette for experimental studies of rAAV-mediated trans…”
BackgroundThree-dimensional tissue-engineered human skeletal muscle model of Pompe disease
Wang, J., Zhou, C. J., Khodabukus, A., Tran, S., Han, S.-O., Carlson, A. L., Madden, L. R., Kishnani, P. S., Koeberl, D. D., & Bursac, N. (2021) · Communications Biology · doi:10.1038/s42003-021-02059-4 · Cited by 48
AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects
Chwalenia, K., Feng, V.-Y., Hemmer, N., Friedrichsen, H. J., Vorobieva, I., Wood, M. J. A., & Roberts, T. C. (2025) · Gene Therapy · doi:10.1038/s41434-025-00561-6 · Cited by 44
Liu, J., Volkers, L., Jangsangthong, W., Bart, C. I., Engels, M. C., Zhou, G., Schalij, M. J., Ypey, D. L., Pijnappels, D. A., & de Vries, A. A. F. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy134 · Cited by 36
Desmin-regulated Lentiviral Vectors for Skeletal Muscle Gene Transfer
Talbot, G., Waddington, S. N., Bales, O., Tchen, R. C., & Antoniou, M. N. (2009) · Molecular Therapy · doi:10.1038/mt.2009.267 · Cited by 41
Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors
Seto, J. T., Ramos, J. N., Muir, L. A., Chamberlain, J. S., & Odom, G. L. (2012) · Current Gene Therapy · doi:10.2174/156652312800840603 · Cited by 43
Self-citationGene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy
Bengtsson, N. E., Tasfaout, H., & Chamberlain, J. S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.065 · Cited by 41
“…C-terminal domain, 96 while Solid Biosciences uses the most recent μ Dys design, which is the only one that enables localization of nNOS to the DGC. 81 Different MSECs are used in the various trials, although all are muscle specific (Sarepta and Roche, MHCK7 97 ; Genethon and RegenexBio, Spc5.”
Self-citationGonçalves, M. A. F. V., Janssen, J. M., Nguyen, Q. G., Athanasopoulos, T., Hauschka, S. D., Dickson, G., & de Vries, A. A. F. (2011) · Molecular Therapy · doi:10.1038/mt.2010.308 · Cited by 36
Self-citationTherapy of Genetic Disorders: Novel Therapies for Duchenne Muscular Dystrophy
Seto, J. T., Bengtsson, N. E., & Chamberlain, J. S. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0044-x · Cited by 41
“Other methods to reduce immune rejection include the use of muscle-specific gene regulatory switches to prevent protein production in non-muscle cells [58–60], sequence-optimization of the therapeutic gene to be delivered to reduce vector dosage [61], and thorough purification from contaminating viral gene products du…”
MethodSelf-citationMartari, M., Sagazio, A., Mohamadi, A., Nguyen, Q., Hauschka, S. D., Kim, E. S., & Salvatori, R. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.197 · Cited by 36
“…number of CK cassettes have been developed with different selectivity and potency, finding applications in the expression of genes in skeletal and heart muscles for the treatment of muscular dystrophies in mice (Wang et al., 2000; Salva et al., 2007) and murine Pompe’s disease (Sun et al., 2008).”
BackgroundMethodInfluentialSelf-citationGantz, J. A., Palpant, N. J., Welikson, R. E., Hauschka, S. D., Murry, C. E., & Laflamme, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046971 · Cited by 34
“5% gelatin coated chamber slides in RPMI-B27 medium supplemented with 10% FBS, 10 uM Y-27632 (Sigma), Polybrene (Millipore) and 5000 particles per cell of a lentivirus expressing Cre under the striated muscle-specific CK7 regulatory cassette, based on the muscle creatine kinase promoter (MCK) [9–11].”
MethodSelf-citationDifferentiation and fiber type-specific activity of a muscle creatine kinase intronic enhancer
Tai, P. W. L., Fisher-Aylor, K. I., Himeda, C. L., Smith, C. L., MacKenzie, A. P., Helterline, D., Angello, J. C., Welikson, R. E., Wold, B. J., & Hauschka, S. D. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-25 · Cited by 36
“The proximal promoter contains at least four active transcription factor binding sites: p53, E-box, CArG, and MPEX, a recently discovered sequence that recruits both Mycassociated zinc finger protein (MAZ) and Krupple-like factor 3 (KLF3) [30-33] Studies involving the systemic delivery of expression constructs via ade…”
BackgroundSelf-citationGraybuck (2019) · doi:10.1101/525014 · Cited by 31
“Concatenation of these natural regulatory elements resulted in higher reporter expression, as previously demonstrated for similar AAV tools targeting cell types in muscle (Salva et al., 2007).”
ResultSynthetic Promoters in Gene Therapy: Design Approaches, Features and Applications
Artemyev, V., Gubaeva, A., Paremskaia, A. I., Dzhioeva, A. A., Deviatkin, A. A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2024) · Cells · doi:10.3390/cells13231963 · Cited by 43
“Often, low-conserved sequences are removed, and the significance of the remaining fragments is confirmed by mutational analysis [102].”
Su, W., Kang, J., Sopher, B., Gillespie, J., Aloi, M. S., Odom, G. L., Hopkins, S., Case, A., Wang, D. B., Chamberlain, J. S., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13081 · Cited by 32
“…since rAAV6 was mostly used in airway (alveolar) cell gene transduction (Halbert et al. 2001) or in striated muscles (Gregorevic et al. 2004; Salva et al. 2007; Gao et al. 2011a). rAAV6 was recently compared with other rAAV serotypes for their tropism toward different CNS cell types in…”
ResultSelf-citationVannoy, C. H., Xiao, W., Lu, P., Xiao, X., & Lu, Q. L. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.02.002 · Cited by 43
“However, for clinical applications, a muscle-specific promoter such as the CK7-based cassette is highly preferred for selective expression in targeted dystrophic muscles.(30) Unfortunately, the CK7-based cassette is slightly more active but very weak compared with the CMV cassette.”
BackgroundKe, Q., Zhao, Z.-Y., Mendell, J. R., Baker, M. W., Wiley, V. C., Kwon, J. M., Alfano, L. N., Connolly, A. M., Jay, C., Polari, H., et al. (2019) · World Journal of Pediatrics · doi:10.1007/s12519-019-00242-6 · Cited by 33
Mendell, J. R., Pozsgai, E. R., Lewis, S., Griffin, D. A., Lowes, L. P., Alfano, L. N., Lehman, K. J., Church, K. R., Reash, N. F., Iammarino, M. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02730-9 · Cited by 35
A Muscle Hybrid Promoter as a Novel Tool for Gene Therapy
Piekarowicz, K., Bertrand, A., Azibani, F., Beuvin, M., Julien, L., Machowska, M., Bonne, G., & Rzepecki, R. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.001 · Cited by 33
“However, after systemic injection of AAV6, the reporter protein level obtained with the MHCK7 cassette was comparable with that obtained with CMV or RSV promoters in skeletal and heart muscles but also in the liver, spleen, and lung.(48) Although CK8, MHCK7, or minimal CKM promoters are currently used in DMD gene ther…”
ResultHarlaar, N., Dekker, S. O., Zhang, J., Snabel, R. R., Veldkamp, M. W., Verkerk, A. O., Fabres, C. C., Schwach, V., Lerink, L. J. S., Rivaud, M. R., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00827-5 · Cited by 35
Gene therapy for muscle disease
Miyagoe‐Suzuki, Y., & Takeda, S. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.05.022 · Cited by 38
Targeted Bmal1 restoration in muscle prolongs lifespan with systemic health effects in aging model
Gutierrez‐Monreal, M. A., Wolff, C. A., Rijos, E. E., Viggars, M. R., Douglas, C. M., Pagala, V., Peng, J., Hunt, L. C., Ding, H., Huo, Z., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.174007 · Cited by 33
Starikova, A. V., Skopenkova, V. V., Polikarpova, A. V., Reshetov, D. A., Vassilieva, S. G., Velyaev, O. A., Shmidt, A. A., Savchenko, I. M., Soldatov, V. O., Egorova, T. V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-04892-x · Cited by 32
Hu, C., Kasten, J., Park, H., Bhargava, R., Tai, D. S., Grody, W. W., Nguyen, Q. G., Hauschka, S. D., Cederbaum, S. D., & Lipshutz, G. S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.99 · Cited by 33
Self-citationMoyes, K. W., Sip, C. G., Obenza, W., Yang, E., Horst, C., Welikson, R. E., Hauschka, S. D., Folch, A., & Laflamme, M. A. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0586 · Cited by 30
“For this, we created a lentiviral vector in which regulatory elements from the striated muscle-specific muscle creatine kinase promoter [26] drive expression of the fluorescent protein, mCherry, and puromycin resistance (Supplementary Fig.”
Self-citationAccelerating promoter identification and design by deep learning
Wang, X., Xu, K., Huang, Z., Lin, Y., Zhou, J., Zhou, L., & Ma, F. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.05.008 · Cited by 32
Viral-based gene delivery and regulated gene expression for targeted cancer therapy
Lu, Y. W., & Madu, C. O. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903419608 · Cited by 26
“Other identified tissue-specific promoters include human calcitonin gene (CALC-I) promoter for thyroid tissue [47,48], and murine muscle creatine kinase promoter for skeletal and cardiac muscle [49-51].”
BackgroundImmunomodulatory Gene Therapy in Lysosomal Storage Disorders
Koeberl, D. D., & Kishnani, P. S. (2009) · Current Gene Therapy · doi:10.2174/156652309790031094 · Cited by 29
“Incorporating an -myosin heavy chain enhancer within the MCK promoter/enhancer, in the regulatory cassette MHCK7, increased transgene activity markedly in the heart and skeletal muscle [35].”
Background
Metadata
- Authors
- Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., Chamberlain, J. S., & Hauschka, S. D.
- Affiliations
- University of Washington (US)
- Corresponding author
- Hauschka, Stephen D
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 15
- Issue
- 2
- Pages
- 320-329
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2065979540
- Cited by
- 232
- References
- 46
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 22 · 2023: 22 · 2022: 11 · 2021: 16 · 2020: 13 · 2019: 12 · 2018: 8 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 7 · 2012: 11
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3536 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R24HL064387)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR018860)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD007183, U54HD047175)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- muscle-specific promoter, muscle creatine kinase, alpha-myosin heavy chain, microdystrophin, mdx mice, skeletal muscle, myocardium, tissue-specific gene expression
- MeSH terms
- Dependovirus, Animals, Cell Line, Cells, Cultured, Cloning, Molecular, Creatine Kinase, Fluorescent Antibody Technique, Gene Expression Regulation, Genetic Vectors, Humans, Male, Mice, Inbred C57BL, Myocardium, Promoter Regions, Genetic, Transfection, Muscle, Skeletal, Ventricular Myosins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.